Vacuolar H(+)-ATPases. Targets for drug discovery?
Keeling
D J
DJ
Preclinical R&D, Astra Hässle AB, Mölndal, Sweden. david.keeling@hassle.se.astra.com
Herslöf
M
M
Ryberg
B
B
Sjögren
S
S
Sölvell
L
L
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001862:Bone Resorption / Q000201:enzymology; D001921:Brain / Q000201:enzymology; D002462:Cell Membrane / Q000201:enzymology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D018942:Macrolides; D008958:Models, Molecular; D010010:Osteoclasts / Q000201:enzymology; D011487:Protein Conformation; D017494:Proton Pumps / Q000737:chemistry / Q000378:metabolism; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D025262:Vacuolar Proton-Translocating ATPases
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D018942:Macrolides; D017494:Proton Pumps; C040929:bafilomycin A1; D025262:Vacuolar Proton-Translocating ATPases; D006180:Proton-Translocating ATPases